On Mar. 7, 2023, Abbott announced that it had received U.S. Food and Drug Administration clearance for what is the first commercially available laboratory traumatic brain injury (TBI) blood test, making it widely available to hospitals in the United States.

The test, which runs on Abbott’s Alinityﾮ i laboratory instrument, will provide clinicians with an objective way to quickly assess individuals with mild TBIs, also known as concussions.